CelAgace™ OraRinse Solution for Treatment of Candidiasis
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated
for safety and effectiveness as a potential treatment for candidiasis, a yeast infection,
commonly known as thrush, which is associated with mouth sores.